35 results
8-K
EX-99.1
GOSS
Gossamer Bio Inc
6 May 24
Entry into a Material Definitive Agreement
7:31am
this therapy to patients world-wide,” said Giuseppe Accogli, Group CEO of Chiesi. “Gossamer shares Chiesi’s commitment to using innovation to promote the health … , the US, and France, Chiesi’s commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making
8-K
EX-99.1
GOSS
Gossamer Bio Inc
12 Mar 24
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan
4:01pm
. With Dr. Nathan’s guidance, Gossamer is poised to expand its clinical program for seralutinib to include PH-ILD, underscoring Gossamer’s commitment
8-K
EX-3.1
hbjdb31lec ssnm
27 Nov 23
Departure of Directors or Certain Officers
4:01pm
8-K
EX-10.1
xfsd4q8tubzmdkxs5ph
20 Jul 23
Gossamer Bio Announces $212 Million Private Placement Financing
4:01pm
PRE 14A
m42 80apz52vdum5e
17 Apr 23
Preliminary proxy
4:01pm
8-K
EX-10.1
jijb t7l71
13 Jul 22
Gossamer Bio Announces $120 million Private Placement Financing
8:45am
8-K
EX-10.1
snoev 0gq8x
2 Jul 20
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
8ep7cpkcp im0w19v9v
3 May 19
Gossamer Bio Secures Debt Facility for Up to $150 Million
4:00pm